Becton Dickinson: Developing the Capability to Innovate 'Outside the Home Court' Custom Case Solution & Analysis

Evidence Brief: Becton Dickinson Case Analysis

Financial Metrics

Total Revenue: 7.16 billion dollars in fiscal year 2008.
Market Leadership: 80 percent of revenue derived from categories where the company holds the number 1 or number 2 market position.
Historical Growth: Sustained double-digit earnings growth over the previous decade.
R and D Investment: Approximately 5 to 6 percent of annual sales, primarily directed toward incremental improvements.
Innovation Goal: Target of 30 percent of revenue from products launched within the last five years.

Operational Facts

Organizational Structure: Three primary segments: BD Medical, BD Diagnostics, and BD Biosciences.
Operational Focus: High proficiency in incremental innovation, termed home court innovation, focusing on line extensions and cost reductions.
Discovery Teams: Six cross-functional teams established to explore white space opportunities outside existing business unit mandates.
Corporate Innovation Council: Established in 2006 to oversee the discovery process and manage the innovation portfolio.
Geographic Reach: Operations in over 50 countries with significant manufacturing footprints in North America, Europe, and Asia.

Stakeholder Positions

Ed Ludwig, CEO: Focused on transitioning the company from an operational excellence firm to an innovation-driven enterprise.
Bill Kozy, Executive Vice President: Advocate for the Discovery Team model and institutionalizing the ability to look beyond current markets.
Gary Cohen, Executive Vice President: Emphasis on global health and the need for innovation to solve large-scale medical problems.
Business Unit Presidents: Generally protective of their P and L statements; often hesitant to fund long-term projects with uncertain returns.

Information Gaps

Specific failure rates and historical costs for previous non-incremental projects.
Detailed breakdown of the 30 percent new product revenue target by segment.
Explicit compensation incentives for Discovery Team members versus Business Unit managers.

Strategic Analysis: Navigating Beyond the Home Court

Core Strategic Question

How can Becton Dickinson institutionalize a capability for breakthrough innovation without compromising the operational efficiency of its core business segments?
How should the company resolve the structural tension between short-term business unit profit goals and long-term corporate growth initiatives?

Structural Analysis

The company faces a classic innovator dilemma. Its current success is built on a high-volume, low-cost manufacturing model. This structure creates a psychological and financial barrier to pursuing high-risk, high-reward opportunities. Applying the Three Horizons framework, Becton Dickinson is dominant in Horizon 1 (core) but lacks the mechanisms to fund and nurture Horizon 3 (disruptive) initiatives. The bargaining power of business unit presidents acts as a constraint on corporate-level innovation, as they control the resources required for commercialization.

Strategic Options

Option	Rationale	Trade-offs
Autonomous Breakthrough Unit	Separate discovery and commercialization from business units to prevent cannibalization of resources.	High independence but risks creating a disconnect from the manufacturing and sales assets of the core firm.
Hybrid Discovery Teams	Maintain cross-functional teams that bridge the gap between corporate vision and business unit execution.	Encourages knowledge transfer but remains vulnerable to business unit budget cuts.
Strategic Acquisition Focus	Use the strong balance sheet to buy companies already operating in white spaces.	Reduces internal R and D risk but requires high premiums and complex integration.

Preliminary Recommendation

Becton Dickinson should adopt the Autonomous Breakthrough Unit model for Horizon 3 projects. The current Discovery Team structure is too dependent on the goodwill of business unit presidents. By ring-fencing a dedicated innovation fund at the corporate level, the company can protect early-stage projects from short-term financial pressure. This unit should report directly to the CEO to ensure strategic alignment.

Implementation Roadmap: Executing the Innovation Strategy

Critical Path

Month 1-2: Establish the BD Ventures Fund with a dedicated 150 million dollar annual budget separate from business unit P and L.
Month 3: Redefine success metrics for Discovery Teams, moving from Net Present Value to Real Options Valuation and milestone-based learning.
Month 4-6: Create a formal hand-off protocol where successful discovery projects are either integrated into a business unit or launched as a new standalone division.
Month 9: Implement a talent rotation program where high-potential managers spend 18 months in Discovery Teams without losing their seniority in the core business.

Key Constraints

P and L Pressure: Business units may view corporate innovation funds as a tax on their performance, leading to internal friction.
Commercialization Gap: The company lacks the sales force and distribution networks for markets outside its current medical and diagnostic domains.
Cultural Inertia: A century of focus on incremental safety improvements makes the organization naturally risk-averse.

Risk-Adjusted Implementation Strategy

To mitigate the risk of commercialization failure, the company must utilize a staged investment approach. Initial funding should only cover proof-of-concept and market validation. Full-scale manufacturing investment should only occur after a pilot program demonstrates clear customer demand. If a project fails to meet its learning milestones within 12 months, it must be terminated immediately to preserve capital for more promising leads.

Executive Review and BLUF

Bottom Line Up Front

Becton Dickinson must decouple the funding and governance of breakthrough innovation from its core business units. The current Discovery Team model is a productive start but remains structurally subservient to short-term P and L targets. To achieve the goal of 30 percent revenue from new products, the company must establish an independent corporate unit with its own investment criteria and leadership. Failure to do so will result in the continued death of high-potential projects during the commercialization phase. The focus must shift from defending the home court to building a portfolio of new growth platforms.

Dangerous Assumption

The most consequential unchallenged premise is that the existing business units possess the desire or the capability to commercialize products that do not fit their current sales models. The analysis assumes that once a Discovery Team identifies an opportunity, a business unit will naturally want to take it to market. In reality, these units are optimized for high-volume efficiency and may reject innovations that require different sales cycles or lower initial margins.

Unaddressed Risks

Execution Risk: The company may struggle to attract top-tier entrepreneurial talent if it insists on maintaining its traditional corporate hierarchy and compensation structures within the new innovation unit.
Market Timing Risk: By the time the internal Discovery Teams validate a white space, more agile startups or venture-backed competitors may have already established a dominant position.

Unconsidered Alternative

The team failed to consider an aggressive Licensing and Partnership model. Instead of building every breakthrough internally, Becton Dickinson could act as the preferred scale-up partner for university spin-offs and small biotech firms. This would allow the company to employ its superior manufacturing and regulatory expertise while outsourcing the high-risk discovery phase to the external market.